Zacks Investment Research lowered shares of Pharming Group (NASDAQ:PHGUF) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

Shares of Pharming Group (PHGUF) opened at 0.57 on Tuesday. Pharming Group has a 1-year low of $0.17 and a 1-year high of $0.58. The stock’s market capitalization is $288.20 million.

WARNING: “Pharming Group (PHGUF) Rating Lowered to Sell at Zacks Investment Research” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/16/pharming-group-phguf-rating-lowered-to-sell-at-zacks-investment-research.html.

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related stocks with our FREE daily email newsletter.